Two long-acting injectable (LAI) preparations of aripiprazole had been available for many years—aripiprazole monohydrate (Abilify Maintena®) and aripiprazole lauroxil (Aristada®). Then, in 2023, another long-acting injectable preparation of aripiprazole was approved by the Food and Drug Administration (FDA)—aripiprazole extended-release injectable suspension (Abilify Asimtufii®). Abilify Asimtufii® has two BIG advantages over Abilify Maintena®, which we’ll discuss…